top of page
Active, not recruiting

NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis

Updated: Feb 10

  • NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis


EMN 22 DARA AMYLOIDOSIS

NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis


This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.


Sponsor


Collaborator

 

ClinicalTrials.gov Identifier: NCT04131309

Official Title: Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

First Posted : October 18, 2019

Click here to see details on ClinicalTrials.gov


 



 

Drug: Daratumumab

Drug: Bortezomib Injection

Drug: Dexamethasone oral tablet

 

Locations

Europe

France

Greece

Italy

Netherlands


Posts Archive
bottom of page